

Quasi-species prevalence and clinical impact of evolving SARS-CoV-2 lineages in European COVID-19 cohorts, January 2020 to February 2022

Multicenter observational study (Jan 2020 - Feb 2022) Italy, Netherlands, Spain, France DOI: https://dx.doi.org/10.2807/1560-7917.ES.2025.30.10.2400038

Core research objectives

To determine how the evolution of the SARS-COV-2 affects severity of COVID-19

To describe prevalence of quasi-species (minority variants within individual patients)

To assess the role of clades, mutations and quasi-species in driving COVID-19 severity



symptomatic patients

1,762 nasopharyngeal swabs from


RNA extraction, RT-qPCR, whole-genome sequencing

Nextclade v2.2.0, Pangolin v1.9

Variant classification:

(WHO scale) 13% (237) Death

Disease severity



Mutation analysis

1,332 high-quality sequences analysed

187 mutations detected, **101** linked to disease severity % of mutations

24.6%

in the Spike gene 12.0% in the

nsp3 gene 5.6%

in the

12.4% in the

Nucleocapsid gene

polymerase gene

of Variants of Concern (VOCs) especially in key viral regions Being immunocompromised,

increased with the emergence

Mutation rates sharply

as well as 27 specific

(quasi-species) was

mutations in SARS-CoV-2 genome were linked to severe disease Intra-host viral diversity

325 mutated positions, 426

unique substitutions across

common among patients

What

A small number of genomic hotspots were

shared across all

variants

Mutational variability across

dynamic nature of the virus

the viral genome highlights the

we learned

the genome VOCs showed higher mutation rates, particularly

Severe cases were linked to specific variants compared to 21J/Delta: 20A/EU2 (OR=2.80),

affecting the S gene **Key findings** on variants and severity

Patients with Delta and

Omicron showed higher

viral loads compared to

Quasi-species indicate

SARS-CoV-2 evolves

pre-Delta variants

within individual patients Mutations occurred equally in base-paired and

suggesting structure did not constrain mutation rates

non-paired regions,



severity, treatment, and vaccine effectiveness We recommend

species may affect associations between variants and disease

including minority variants in future molecular epidemiology and transmission studies

We propose representing mutation probabilities within patient samples to capture minority subvariants

Public Health Implications

the information it contains.



The ORCHESTRA project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101016167. The views expressed in this document are the sole responsibility of the author and the Commission is not responsible for any use that may be made of

Read more at orchestra-cohort.eu